Tumor cell death in orthotopic breast cancer model by NanoALA: a novel perspective on photodynamic therapy in oncology

Author:

de Andrade Laise R1ORCID,Tedesco Antonio C2,Primo Fernando L3,Farias Gabriel R1,da Silva Jaqueline R1ORCID,Longo João PF1,de Almeida Marcos C1,de Souza Paulo EN4,de Azevedo Ricardo B1,Pinheiro Willie O15,Lacava Zulmira GM1

Affiliation:

1. Department of Genetics & Morphology, Institute of Biological Sciences, University of Brasília, 70910-900, Brasília, DF, Brazil

2. Department of Chemistry, Center of Nanotechnology & Tissue Engineering – Photobiology & Photomedicine Research Group, Faculty of Philosophy, Sciences & Letters of Ribeirão Preto, University of São Paulo, 14010-100, Ribeirão Preto, Brazil

3. Department of Engineering of Bioprocesses and Biotechnology, School of Pharmaceutical Sciences, São Paulo State University, 14800-903, Araraquara, SP, Brazil

4. Laboratory of Electron Paramagnetic Resonance, Institute of Physics, University of Brasília, 70919-970, Brasília, DF, Brazil

5. Post-Graduation Program in Sciences & Technologies in Health, Faculty of Ceilândia, University of Brasília, 72220-275, Brasília, DF, Brazil

Abstract

Aim: Nano-5-aminolevulic acid (NanoALA)-mediated photodynamic therapy (PDT), an oil-in-water polymeric nanoemulsion of ALA, was evaluated in a murine model of breast cancer. Materials & methods: Analysis of ALA-derived protoporphyrin IX production and acute toxicity test, biocompatibility and treatment efficacy, and long-term effect of NanoALA-PDT on tumor progression were performed. Results: The nanoformulation favored the prodrug uptake by tumor cells in a shorter time (1.5 h). As a result, the adverse effects were negligible and the response rates for primary mammary tumor control were significantly improved. Tumor progression was slower after NanoALA-PDT treatment, providing longer survival. Conclusion: NanoALA is a good proactive drug candidate for PDT against cancer potentially applied as adjuvant/neoadjuvant intervention strategy for breast cancer.

Publisher

Future Medicine Ltd

Subject

Development,General Materials Science,Biomedical Engineering,Medicine (miscellaneous),Bioengineering

Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3